• Study Resource
  • Explore
    • Arts & Humanities
    • Business
    • Engineering & Technology
    • Foreign Language
    • History
    • Math
    • Science
    • Social Science

    Top subcategories

    • Advanced Math
    • Algebra
    • Basic Math
    • Calculus
    • Geometry
    • Linear Algebra
    • Pre-Algebra
    • Pre-Calculus
    • Statistics And Probability
    • Trigonometry
    • other →

    Top subcategories

    • Astronomy
    • Astrophysics
    • Biology
    • Chemistry
    • Earth Science
    • Environmental Science
    • Health Science
    • Physics
    • other →

    Top subcategories

    • Anthropology
    • Law
    • Political Science
    • Psychology
    • Sociology
    • other →

    Top subcategories

    • Accounting
    • Economics
    • Finance
    • Management
    • other →

    Top subcategories

    • Aerospace Engineering
    • Bioengineering
    • Chemical Engineering
    • Civil Engineering
    • Computer Science
    • Electrical Engineering
    • Industrial Engineering
    • Mechanical Engineering
    • Web Design
    • other →

    Top subcategories

    • Architecture
    • Communications
    • English
    • Gender Studies
    • Music
    • Performing Arts
    • Philosophy
    • Religious Studies
    • Writing
    • other →

    Top subcategories

    • Ancient History
    • European History
    • US History
    • World History
    • other →

    Top subcategories

    • Croatian
    • Czech
    • Finnish
    • Greek
    • Hindi
    • Japanese
    • Korean
    • Persian
    • Swedish
    • Turkish
    • other →
 
Profile Documents Logout
Upload
As we know, there are two main areas of pharmacology, they are
As we know, there are two main areas of pharmacology, they are

... ions, glucose and amino acids. The action of the sodium-potassium pump is an example of active transport, you’ll discuss it in 24 chapter, in drugs used heart failure. As to facilitated diffusion, it is a process of passive transport without needing energy. In facilitated diffusion, the solutes move ...
In Vitro Kinetic Characterization of Axitinib Metabolism
In Vitro Kinetic Characterization of Axitinib Metabolism

... and 16.2% of circulating radioactivity, respectively. Clinical drug interaction studies with axitinib as an object or victim drug have been conducted in combination with ketoconazole and rifampin as strong inhibitors and inducers, respectively, of CYP3A and the respective changes in axitinib plasma ...
nanotechnology-based cosmeceuticals: a review
nanotechnology-based cosmeceuticals: a review

... drawbacks associated with the traditional products. The nanotechnology-based delivery techniques have proved to offer advantages of greater stability, higher efficacy and have also been reported to show prolonged effects. Nanoparticles are also proficient in modifying the flux, targeting the drug to ...
summation of decisions concerning marketing of prescription
summation of decisions concerning marketing of prescription

... Oy had been requested to abstain from incorrect marketing and imposed a sanction payment of 15 000 euros (Decision 13/2005 by Supervisory Commission is about AstraZeneca Oy’s complaint in that matter), the complaint was dismissed. Decision in October 26th 2005, advertisement about psoriasis Inspecti ...
Sucroferric oxyhydroxide - Therapeutic Goods Administration
Sucroferric oxyhydroxide - Therapeutic Goods Administration

... At the time the TGA considered this application, a similar application had been approved in the European Union (EU, August 2014) and the USA (November 2013) and was under evaluation in Switzerland and Singapore. Product Information The approved Product Information (PI) current at the time this AusPA ...
Overview of drug-interactions between coumarin
Overview of drug-interactions between coumarin

Metronidazole - American Academy of Veterinary Pharmacology
Metronidazole - American Academy of Veterinary Pharmacology

Formulation Considerations of Inhaled Products
Formulation Considerations of Inhaled Products

... in the liquefied propellant (HFA134a or 227) ...
Chapter 1 Introduction
Chapter 1 Introduction

... 【Reference teaching material】 1. Gao Yingmao, Histology&Embryology, second edition, People’s Medical publishing House,2010. 2.Michael H. Ross & Wojciech Pawlina. Histology(A text and Atlas) 6th edition.Williams&Wilkins,2010. Chapter 7 Cell& tissue adaptation and injury Course: Human structure and fu ...
Multi compartment models (Delayed distribution models)
Multi compartment models (Delayed distribution models)

... • Ideally a true pharmacokinetic model should be the one with a rate constant for each tissue undergoing equilibrium. • Therefore best approach is to pool together tissues on the basis of similarity in their distribution characteristics. • The drug disposition occurs by first order. • Multi-compart ...
Long-acting Beta-Agonists with and without Inhaled Corticosteroids and Catastrophic Asthma Events
Long-acting Beta-Agonists with and without Inhaled Corticosteroids and Catastrophic Asthma Events

... this meta-analysis are based on a relatively small number of events, so they should be interpreted with caution. However, these findings provide evidence that long-acting ␤-agonists are associated with significant risk, even when used with concomitant inhaled corticosteroids. This is the first meta- ...
Pipeline/Commercial Insight: Molecular Targeted Cancer
Pipeline/Commercial Insight: Molecular Targeted Cancer

... joined Erbitux and Avastin in the metastatic colorectal cancer market. These new agents are all expected to perform well over the forecast period with an aggregate level of sales reaching $2.77 billion in 2015. ...
IntelGenx Technologies Corp.
IntelGenx Technologies Corp.

... technology, and (3) a Mucoadhesive Tablet technology. Our Multilayer Tablet platform technology allows for the development of oral controlled-release products. It is designed to be versatile and to reduce manufacturing costs as compared to competing oral extended-release delivery technologies. The O ...
Pharmacovigilance in Ghana: A Systems Analysis, April 2010
Pharmacovigilance in Ghana: A Systems Analysis, April 2010

... functional information and technology infrastructure, and collaboration with the World Health Organization (WHO) Collaborating Center for International Drug Monitoring in Uppsala, Sweden (UMC). However, across all levels (national, public health programs, and health treatment facilities), lack of a ...
References - Specialist Pharmacy Service
References - Specialist Pharmacy Service

A theory of drug tolerance and dependence I
A theory of drug tolerance and dependence I

... shows that after the body has learned to cope with this particular disturbance, the increase in thermogenesis on entering the cold and its decrease on return to the room will take place rapidly, while the level of adaptation has increased considerably. 2.3. The detection of exogenous substances The ...
Drug List - The North Carolina Office of EMS
Drug List - The North Carolina Office of EMS

... Only Medications included in the 2012 NCCEP Protocols are included in this document. For a full list of medications approved for use by EMS professionals, please refer to the North Carolina Medical Board document entitled: Approved Medications for Credentialed EMS Personnel. Individual systems shoul ...
Chapter-1 Introduction 1.1 INTRODUCTION
Chapter-1 Introduction 1.1 INTRODUCTION

... importance in the design of dosage forms. Recently, more stress is laid down on the development of organoleptically elegant and patient friendly drug delivery system for paediatric and geriatric patients (Bhusan SY,2000, Wadhwani AR, 2004). Many patients, elderly people and person with dysphagia fin ...
Factory Farms, Antibiotics and Anthrax
Factory Farms, Antibiotics and Anthrax

... 600,000 to 157,000 over the last 15yrs, while # of factory hog farms up 75% • 1 hog farm in NC generates as much sewage annualy as all of Manhattan ...
Powerpoint template for scientific posters (Swarthmore College)
Powerpoint template for scientific posters (Swarthmore College)

... containing these powerful free-radical scavenging properties. Their deep red color brings bountiful health benefits through providing the antioxidant properties of anthocyanins. The American Chemical Society stated that, “100 g of fresh and pitted cherries (20 cherries) contain 12.5-25.0 mg of antho ...
IN VITRO MICROSPHERES
IN VITRO MICROSPHERES

... 5-Flurouracil (5-FU) is an antimetabolite with a broad spectrum activity against solid tumors. However, it’s very short half- life in plasma circulation greatly limited the in vivo antitumor efficacy and clinical application of the drug. The current research work aimed to solve this problem by prepa ...
In vitro - In vivo Correlation: From Theory to
In vitro - In vivo Correlation: From Theory to

... J Pharm Pharmaceut Sci (www. cspsCanada.org) 9 (2): 169-189, 2006 ...
Controlling drug delivery
Controlling drug delivery

REVIEW Chiral Toxicology: It`s the Same Thing...Only Different
REVIEW Chiral Toxicology: It`s the Same Thing...Only Different

... as the differential actions and toxicities of enantiomers became more evident, and as the technology for chiral drug development and detection advanced (U.S. Food and Drug Administration, 1992). Identified chiral-specific issues included appropriate manufacturing controls (exclusion of diastereomeri ...
SEIKO ABUBAKARI - Kwame Nkrumah University of Science
SEIKO ABUBAKARI - Kwame Nkrumah University of Science

... formulated product. Changes in percentage contents and pH were used as a tool for the study. UV-spectrophotometer was used for the analysis. This was done by preparing different concentrations of pure quinine sulphate in 0.1 M HCl solution and their respective absorbance determined at 250 nm. A cali ...
< 1 ... 15 16 17 18 19 20 21 22 23 ... 193 >

Biosimilar

A biosimilar (also known as follow-on biologic or subsequent entry biologic) is a biologic medical product which is a copy of an original product that is manufactured by a different company. Biosimilars are officially approved versions of original ""innovator"" products, and can be manufactured when the original product's patent expires. Reference to the innovator product is an integral component of the approval.Unlike the more common small-molecule drugs, biologics generally exhibit high molecular complexity, and may be quite sensitive to changes in manufacturing processes. Follow-on manufacturers do not have access to the originator's molecular clone and original cell bank, nor to the exact fermentation and purification process, nor to the active drug substance. They do have access to the commercialized innovator product.Drug related authorities such as European Medicines Agency (EMA), Food and Drug Administration (FDA), and Health Canada hold their own guidance on requirements for demonstration of the similar nature of two biological products in terms of safety and efficacy. According to them, analytical studies that demonstrate that the biological product is highly similar to the reference product notwithstanding minor differences in clinically inactive components; animal studies (including the assessment of toxicity); and a clinical study or studies (including the assessment of immunogenicity and pharmacokinetics or pharmacodynamics) that are sufficient to demonstrate safety, purity, and potency in one or more appropriate conditions of use for which the reference product is licensed and intended to be used and for which licensure is sought for the biological product.In case of a monoclonal antibody-containing medicinal product, such as Remsima, extensive physicochemical and biological characterization for it and its reference product Remicade was conducted in order to demonstrate their highly similar properties. Consequently, EMA have granted a marketing authorisation for only a few numbers of biosimilars since 2006 including a monoclonal antibody which is recently approved. Meanwhile, on March 6, 2015, the FDA approved the United States's first biosimilar product, the biosimilar filgrastim Zarxio.
  • studyres.com © 2025
  • DMCA
  • Privacy
  • Terms
  • Report